BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu J, Li Z, Zhang W, Lu H, Sun Z, Wang G, Han X. Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients. Front Pharmacol 2021;12:709060. [PMID: 34733154 DOI: 10.3389/fphar.2021.709060] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhu D, Ma K, Yang W, Zhou H, Shi Q, Ren J, Xie Y, Liu S, Shi H, Zhou W. Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1057560] [Reference Citation Analysis]
2 Guo B, Zhou Y, Ouyang T, Liu Z, Xia F, Chen Q, Chen X, Xiao Z. TACE plus PD-1 successfully achieves conversion therapy for unresectable HCC with multiple macrovascular invasion: a case report.. [DOI: 10.21203/rs.3.rs-2221582/v1] [Reference Citation Analysis]
3 Xia W, Zhao X, Guo Y, Cao G, Wu G, Fan W, Yao Q, Xu S, Guo C, Hu H, Li H. Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma: A multicenter retrospective study. Front Oncol 2022;12:961394. [DOI: 10.3389/fonc.2022.961394] [Reference Citation Analysis]
4 Sun L, Xu X, Meng F, Liu Q, Wang H, Li X, Li G, Chen F. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review. Front Oncol 2022;12:980214. [DOI: 10.3389/fonc.2022.980214] [Reference Citation Analysis]
5 Yin L, Liu K, Lv W, Xu S, Lu D, Zhou C, Cheng D, Gao Z, Shi C, Su M. Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation. DDDT 2022;Volume 16:3421-3429. [DOI: 10.2147/dddt.s372276] [Reference Citation Analysis]
6 Ke Q, Xin F, Fang H, Zeng Y, Wang L, Liu J. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review. Front Immunol 2022;13:913464. [DOI: 10.3389/fimmu.2022.913464] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Ju S, Zhou C, Hu J, Wang Y, Wang C, Liu J, Yang C, Huang S, Li T, Chen Y, Bai Y, Yao W, Xiong B. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09451-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
8 Cai M, Huang W, Huang J, Shi W, Guo Y, Liang L, Zhou J, Lin L, Cao B, Chen Y, Zhou J, Zhu K. Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study. Front Immunol 2022;13:848387. [PMID: 35300325 DOI: 10.3389/fimmu.2022.848387] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
9 Yang F, Xu G, Huang J, Yin Y, Xiang W, Zhong B, Li W, Shen J, Zhang S, Yang J, Sun HP, Wang W, Zhu X. Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response. Front Immunol 2022;13:847601. [DOI: 10.3389/fimmu.2022.847601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Huang J, Zhang S, Yang Y, Zhang Z, Jiang N, Li W, Shen J, Zhong B, Zhu X. Recent Update on Immunotherapy and Its Combination With Interventional Therapies for Hepatocellular Carcinoma. Clin Med Insights Oncol 2022;16:117955492211348. [DOI: 10.1177/11795549221134832] [Reference Citation Analysis]
11 Multiple drugs. Reactions Weekly 2021;1884:292-292. [DOI: 10.1007/s40278-021-06613-4] [Reference Citation Analysis]